Spondyloarthritis phenotypes: rationale of evaluation in context of personified medicine

The article contents the analysis of different clinical phenotypes in the most common spondyloarthritis (SpA): ankylosing spondylitis (AS), axial spondylarthritis (axSpA) and psoriatic arthritis (PsA). SpA polymorphism has been discussed on the basis of multiple clinical presentations, structural lesions, radiological, immunological and genetic characteristics. Role of pro-inflammatory agents especially IL-17 in structural progression has been pointed out. Recent data regarding the link between HLA-B27 antigen, gender and age specificity and different clinical manifestation of SpA are presented. Current algorithms for SpA management based on evidence of efficacy sDMARD and/or biologics in separate phenotypes of SpA as well as resistance to DMARD are highlighted. Authors have concluded that meticulous analysis of SpA manifestation and patient’s individual profile is critical in rational SpA management according to personified medicine strategy.

[1]  J. Primdahl,et al.  EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update , 2020, Annals of the Rheumatic Diseases.

[2]  R. Moots,et al.  The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies , 2019, Annals of the rheumatic diseases.

[3]  M. D’Agostino,et al.  SAT0308 CLUSTER-BASED SPONDYLOARTHRITIS PHENOTYPES DEFINED AT BASELINE ARE PREDICTIVE OF 5-YEAR SEVERITY OUTCOME IN THE DESIR COHORT , 2019, Saturday, 15 June 2019.

[4]  G. Kollias,et al.  FRI0162 The link between angiogenesis and osteogenesis in spondyloarthritis , 2018, FRIDAY, 15 JUNE 2018.

[5]  Correction: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2018, Annals of the rheumatic diseases.

[6]  M. Dougados,et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2017, Annals of the rheumatic diseases.

[7]  L. Gensler,et al.  FRI0474 Does axial spondyloarthritis phenotype correlate with imaging morphotype? , 2017 .

[8]  J. Askling,et al.  OP0240 How strong are the associations of spondyloarthritis-related comorbidities with ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis? a register-based study from sweden , 2017 .

[9]  M. Dougados,et al.  Tracking JAKs in spondyloarthritis: rationale and expectations , 2017, Annals of the rheumatic diseases.

[10]  Е. Л. Насонов,et al.  Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17 , 2017 .

[11]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[12]  R. Landewé,et al.  Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis , 2017, RMD Open.

[13]  M. Dougados,et al.  2016 update of the EULAR recommendations for the management of early arthritis , 2016, Annals of the rheumatic diseases.

[14]  A. Jobling,et al.  Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis , 2016, Annals of the rheumatic diseases.

[15]  D. M. van der Heijde,et al.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study , 2016, Annals of the rheumatic diseases.

[16]  Татьяна Викторовна Коротаева.  Перспективы применения ингибиторов интерлейкина 17 - нового класса препаратов для таргетной терапии псориатического артрита , 2016 .

[17]  Y. Shibasaki,et al.  Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study , 2016, The Journal of dermatology.

[18]  M Cutolo,et al.  European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.

[19]  D. Veale,et al.  Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors , 2015, Annals of the rheumatic diseases.

[20]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[21]  Шандор Федорович Эрдес.  Основные принципы терапии анкилозирующего спондилита (болезни Бехтерева) , 2014 .

[22]  J. Bijlsma,et al.  FRI0459 Hla-b27 positive versus hla-b27 negative spondyloarthritis: different phenotypes but similar disease burden , 2013 .

[23]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general , 2010, Annals of the rheumatic diseases.